Haemonetics (NYSE:HAE) Releases FY 2025 Earnings Guidance

Haemonetics (NYSE:HAE) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.450-4.750 for the period, compared to the consensus estimate of 4.600. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Haemonetics also updated its FY25 guidance to $4.45 to $4.75 EPS.

Haemonetics Trading Up 0.8 %

Shares of NYSE HAE traded up $0.60 during midday trading on Friday, hitting $77.03. The company’s stock had a trading volume of 848,252 shares, compared to its average volume of 525,351. The business’s 50 day moving average is $86.50 and its two-hundred day moving average is $84.13. Haemonetics has a 12-month low of $70.74 and a 12-month high of $97.97. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83. The firm has a market cap of $3.92 billion, a P/E ratio of 33.64, a price-to-earnings-growth ratio of 1.64 and a beta of 0.29.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.01). The business had revenue of $336.17 million for the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The firm’s revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.05 earnings per share. As a group, equities research analysts expect that Haemonetics will post 4.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HAE. Barrington Research upped their price objective on Haemonetics from $107.00 to $108.00 and gave the stock an outperform rating in a research note on Friday. JMP Securities increased their price target on shares of Haemonetics from $115.00 to $125.00 and gave the company a market outperform rating in a research report on Friday, May 10th. Finally, Needham & Company LLC raised shares of Haemonetics from a hold rating to a buy rating and set a $112.00 price objective on the stock in a research report on Wednesday, June 12th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics has an average rating of Moderate Buy and an average price target of $109.75.

Insider Activity at Haemonetics

In other news, insider Stewart W. Strong sold 8,857 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $87.53, for a total transaction of $775,253.21. Following the transaction, the insider now owns 18,196 shares in the company, valued at $1,592,695.88. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Stewart W. Strong sold 8,857 shares of Haemonetics stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $87.53, for a total transaction of $775,253.21. Following the completion of the sale, the insider now directly owns 18,196 shares in the company, valued at $1,592,695.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Stewart W. Strong sold 733 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total value of $70,397.32. Following the completion of the transaction, the insider now directly owns 15,608 shares in the company, valued at $1,498,992.32. The disclosure for this sale can be found here. Insiders have sold 31,523 shares of company stock valued at $2,812,120 in the last ninety days. Corporate insiders own 1.80% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.